Sarah Bou Malham, MD
Endocrinology, Diabetes & Metabolism · Edina, MNNPI 1720392590
Payments from drug & device makers
Across 30 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$92
- Novartis$66
- Boehringer Ingelheim$55
- Bayer$49
- Mannkind Corporation$42
- Insulet Corporation$41
- plus $203 from 11 others
What the payments were for
- Food & beverage$53798%
- Education$112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 4 | $92 |
| Novartis | 4 | $66 |
| Boehringer Ingelheim | 3 | $55 |
| Bayer | 3 | $49 |
| Mannkind Corporation | 2 | $42 |
| Insulet Corporation | 2 | $41 |
| Abbott | 2 | $35 |
| AstraZeneca | 1 | $24 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Pfizer | 1 | $18 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
| BETA Bionics, Inc. | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $11 |
How this compares
$549 in reported general payments places this provider in the 45th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Teriparatide | 39 | $116,056 |
| TymlosAbaloparatide | 12 | $31,183 |
| OzempicSemaglutide | 15 | $27,826 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,599 |
| Levothyroxine Sodium | 69 | $1,218 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 17 | $1,036 |
| Alendronate Sodium | 52 | $579 |
| Methimazole | 36 | $542 |
| Hydrocortisone | 16 | $506 |
| Metformin Hcl ErMetformin Hcl | 11 | $84 |
| Metformin Hcl | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Edina
- Thomas LaedtkeEdina$39K
- John ChowEdina$3K
- Elizabeth HaglindEdina$3K
- Anders CarlsonSt Louis Park$5.6M
- Irina BancosRochester$4.8M
- Richard BergenstalSt Louis Park$4M
- Yogish KudvaRochester$2.9M
- Marius StanRochester$2.2M
- John MorrisRochester$1.9M
- Adrian VellaRochester$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.